Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance

JOSEPH A. BAUER, JOSEPH A. LUPICA, JOSEPH A. DIDONATO and DANIEL J. LINDNER
Anticancer Research December 2020, 40 (12) 6751-6763; DOI: https://doi.org/10.21873/anticanres.14698
JOSEPH A. BAUER
1Nitric Oxide Services, LLC, St. John Paul II Center for Science Innovation, North Canton, OH, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOSEPH A. LUPICA
2Department of Math & Sciences, Walsh University, North Canton, OH, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOSEPH A. DIDONATO
3Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DANIEL J. LINDNER
4Translational Hematology Oncology Research (THOR), Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lindned@ccf.org didonaj@ccf.org
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Effects of nitrosylcobalamin (NO-Cbl), Apo2L/TRAIL, and their combination on the proliferation of melanoma cell lines A375, WM9, and WM3211 and normal cell lines CMN1, DMN1, and primary HFF fibroblasts. Left panels: Cells were treated with NO-Cbl (open bars), Apo2L/TRAIL (hatched bars), or pre-treated with NO-Cbl followed by Apo2L/TRAIL (solid bars) for three days, and growth was measured by the colorimetric sulforhodamine B assay (44). Data points represent the mean of four replicates±standard error of the mean (SEM). Right panels: Synergy between NO-Cbl and Apo2L/TRAIL was determined by median effect analysis (48), (combination index >1 indicates antagonism, =1 indicates additivity, and <1 indicates synergy). (a) The sequential treatment of NO-Cbl and Apo2L/TRAIL induced synergistic antiproliferative activity in A375, WM9 and WM3211 cells at each combined dose. (b) Normal melanocyte CMN1 and DMN1 cell lines, and normal HFF fibroblasts were completely resistant to simultaneous exposure to NO-Cbl, Apo2L/TRAIL, or the pre-treatment with NO-Cbl followed by Apo2L/TRAIL.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Effect of NO-Cbl, Apo2L/TRAIL and the combination on the growth of A375 melanoma xenografts. NCR male athymic nude (nu/nu) mice were injected subcutaneously with 4×106 A375 cells (n=8 per group). Drug treatments began on day 2 after injection of tumor cells. NO-Cbl was administered twice daily for the duration of the study. Apo2L/TRAIL was administered every other day. Control mice received phosphate buffered saline. Tumor volume was measured three times per week. Data points represent the mean tumor volume (mm3)±SEM.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    TUNEL apoptosis assay. A375 cells were treated with NO-Cbl, Apo2L/TRAIL, and their combination. NO-Cbl and Apo2L/TRAIL were minimally effective as single agents but demonstrated greater apoptosis when administered concomitantly. The highest levels of apoptosis were observed when cells were pre-treated with NO-Cbl for 12 h followed by Apo2L/TRAIL treatment for 24 h. Conversely, the effect of Apo2L/TRAIL followed by NO-Cbl was no different than Apo2L/TRAIL alone.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    NF-κB-luc reporter assay. NF-κB-luc transfected A375 cells were pre-treated with NO-Cbl for 1 h followed by Apo2L/TRAIL or TNF-α for 4 h. Renilla luciferase was co-transfected to normalize samples for transfection efficiency. Cell lysates were analyzed for NF-κB-luc reporter activity. NO-Cbl pre-treatment inhibited Apo2L/TRAIL- and TNF-α-induced activation of the NF-κB-luc reporter.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Western blot analysis of IκBα and phospho-IκBα. A375 cells were pre-treated for 16 h with NO-Cbl followed by Apo2L/TRAIL or TNF-α stimulation. IκBα and phospho-IκBα protein levels were determined in A375 whole-cell lysates. (a) After stimulation with Apo2L/TRAIL (30 min) or TNF-α (15 min), IκBα was almost totally degraded. NO-Cbl efficiently blocked IκBα degradation following Apo2L/TRAIL, but only partially blocked IκBα degradation following TNF-α. (b) After 1 h, cellular levels of IκBα are restored as a result of re-synthesis. NO-Cbl blocks the phosphorylation of newly translated IκBα. Band retardation of IκBα is evident following Apo2L/TRAIL or TNF-α stimulation. Phospho-IκBα migrates slower than IκBα (compare middle two lanes to other four lanes). c, NO-Cbl, NOC-18, and SNAP pre-treatment all inhibited Apo2L/TRAIL-induced IκBα phosphorylation.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    IκB kinase (IKK) activity. IKK activity was assessed using recombinant GST-IκBα(1-54) and γ32P-ATP as substrates. The phosphorylated GST fusion protein was detected by autoradiography. (a) IKK activity was determined in A375 cells pre-treated with NO-Cbl followed by Apo2L/TRAIL or TNF-α stimulation for 30 min and 15 min, respectively. NO-Cbl treatment inhibited IKK activity more effectively when Apo2L/TRAIL was the stimulus, compared to stimulation by TNF-α. Anti-β-actin antibody served as the irrelevant antibody with no phosphorylation of GST-IκBα(1-54) observed. (b) Coomassie blue-stained gel shows equal loading of GST-IκBα(1-54) substrate. (c) Immunoblot analysis shows the presence of equal amounts of total IKK in the lysates. β-actin was used as a loading control.

PreviousNext
Back to top

In this issue

Anticancer Research: 40 (12)
Anticancer Research
Vol. 40, Issue 12
December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance
JOSEPH A. BAUER, JOSEPH A. LUPICA, JOSEPH A. DIDONATO, DANIEL J. LINDNER
Anticancer Research Dec 2020, 40 (12) 6751-6763; DOI: 10.21873/anticanres.14698

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance
JOSEPH A. BAUER, JOSEPH A. LUPICA, JOSEPH A. DIDONATO, DANIEL J. LINDNER
Anticancer Research Dec 2020, 40 (12) 6751-6763; DOI: 10.21873/anticanres.14698
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Comprehensive Analysis of KREMEN2 as an Immunotherapeutic and Prognostic Biomarker in Pan-Cancer
  • PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
  • Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma
Show more Experimental Studies

Similar Articles

Keywords

  • Apo2L/TRAIL
  • nitric oxide
  • nuclear factor kappa B
  • inhibitor kappa B kinase
  • apoptosis
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire